Is there a progression‐free survival benefit of first‐line crizotinib versus standard chemotherapy and second‐line crizotinib in ALK‐positive advanced lung adenocarcinoma? A retrospective study of Chinese patients

Although crizotinib has demonstrated promising efficacy and acceptable toxicity in patients with advanced non‐small cell lung cancer (NSCLC), the available evidence in Chinese populations is currently limited. This study compared the progression‐free survival (PFS) of Chinese patients with anaplasti...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Shaohua, Zhao, Yizhuo, Dong, Lili, Gu, Aiqin, Xiong, Liwen, Qian, Jialin, Zhang, Wei, Niu, Yanjie, Pan, Feng, Jiang, Liyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924358/
https://www.ncbi.nlm.nih.gov/pubmed/26880708
http://dx.doi.org/10.1002/cam4.659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924358/
https://www.ncbi.nlm.nih.gov/pubmed/26880708
http://dx.doi.org/10.1002/cam4.659

Ejemplares similares